Tracky Introduces 16-Day Continuous Glucose Monitoring System in India

Tracky, the medical device brand of Drstore Healthcare Services, has launched Tracky 16D, which the company describes as India’s first 16-day continuous glucose monitoring (CGM) system.

The wearable provides up to 16 days of continuous glucose data, compared with the commonly available 14-day monitoring period. The extended sensor life could reduce the number of sensor changes, with the company estimating around 22 patches annually compared with 27–28 for shorter-duration systems.

Glucose Data Combined with Lifestyle Metrics

Tracky 16D is designed to provide continuous glucose insights alongside information on nutrition, physical activity, medication, sleep, blood pressure and body composition.

According to the company, the system has a reported mean absolute relative difference (MARD) of 8.58%. It combines the sensor and transmitter into a compact wearable and supports Bluetooth auto-sync and Nightscout integration.

Potential Use in Clinical Follow-Up

For doctors, the key advantage is access to continuous glucose patterns rather than isolated glucose readings. The additional data may help clinicians assess how food, exercise, medication, sleep and daily routines correlate with changes in glucose levels.

Also Read |  Global TB Efforts Stalled: WHO Calls for Emergency Action

The platform also allows doctors to review available glucose reports and patterns during consultations and follow-up visits, while family members and caregivers can monitor information remotely.

AI-Powered Connected Health Platform

The company is positioning Tracky 16D as part of a broader connected cardiometabolic health platform. AI-powered health assistance and the redesigned Tracky Health interface are intended to bring multiple health signals together in one ecosystem.

Neeraj Katare, Founder, Tracky, said the longer monitoring period can give patients and doctors a clearer view of glucose patterns and factors influencing them.

For clinicians, the system’s relevance will ultimately depend on data accuracy, clinical validation, interoperability and how effectively continuous data can support individualised diabetes and cardiometabolic care.